Drug analysis: Vectibix

Drug analysis: Vectibix

  • December 2017 •
  • 23 pages •
  • Report ID: 5336364
Drug Overview
Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents the activation of EGFR and halts the cascade of intracellular signals dependent on this receptor.

Preclinical studies have shown that Vectibix results in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.